Renaissance Technologies LLC Buys Shares of 32,446 SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)

Renaissance Technologies LLC bought a new stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 32,446 shares of the company’s stock, valued at approximately $39,000.

Separately, Anson Funds Management LP acquired a new stake in SELLAS Life Sciences Group during the 1st quarter worth approximately $4,881,000. 17.38% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Royal Bank of Canada upgraded shares of SELLAS Life Sciences Group to a “moderate buy” rating in a report on Monday, June 24th.

SELLAS Life Sciences Group Stock Performance

Shares of SLS stock opened at $1.25 on Tuesday. The company has a market capitalization of $72.19 million, a P/E ratio of -1.14 and a beta of 2.39. The company’s 50 day moving average price is $1.25 and its two-hundred day moving average price is $1.28. SELLAS Life Sciences Group, Inc. has a 52 week low of $0.50 and a 52 week high of $1.72.

SELLAS Life Sciences Group (NASDAQ:SLS) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Analysts forecast that SELLAS Life Sciences Group, Inc. will post -0.55 earnings per share for the current year.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.